Mito Finance Review 2026: Injective Trading and Yield

Mito Finance is listed on Injective and is described as a protocol for automated trading, launchpads, real-world assets and yield generation. The available product information does not explain its strategies, supported assets or user flows, so it is difficult to judge what a user can currently do with it.

Two audits are listed, but their scope and findings are not identified. Fees and team details are not published.

Mito is categorized as a liquidity manager and describes itself as offering automated trading, launchpads, real-world assets and yield generation on Injective. In general, a liquidity manager coordinates assets across strategies or markets; Mito does not publish enough detail to establish which strategies it uses or how funds are allocated.

The protocol's descriptions do not specify how users enter or exit strategies, what assets are involved, or how returns are generated. Treat any yield expectations as uncertain until the underlying mechanism, costs and risks are clearly explained.

Mito Finance does not publish a fee schedule in the information available on its website. Check the app and any relevant transaction or strategy details for costs before committing funds.

Two audits are listed for Mito Finance, but the auditors, audit dates, scope and findings are not identified. That makes it difficult to assess what was reviewed or whether any issues remain. The specific smart-contract design, custody arrangements and strategy risks are also not explained.

Regulatory status is not published. Review the protocol's terms and risk disclosures before using it; interacting with onchain contracts can involve loss of funds.

Mito Finance may be worth investigating for users already active on Injective who want to explore automated trading or yield products. It is a poor fit for anyone who needs clearly documented strategy mechanics, costs or audit findings before deciding where to place funds.